Jessica Feig
Brooklyn, NYNPI 1629465232
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Regeneron at 33.7% of the total. 2025 is the largest year on record at $6,179, more than ten times the $220 reported in 2019.
Across 241 payments — averaging $73.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$6K
- Sanofi$5K
- Pfizer$861
- AbbVie$765
- Sun Pharmaceutical Industries Inc.$559
- Regeneron Healthcare Solutions, Inc.$496
- plus $4K from 22 others
What the payments were for
- Consulting fees$5,61032%
- Speaking & faculty fees$4,46625%
- Travel & lodging$240%
- Food & beverage$7,46942%
- Education$981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 7 | $5,955 |
| Sanofi | 10 | $4,771 |
| Pfizer | 25 | $861 |
| AbbVie(2 entities) | 51 | $765 |
| Sun Pharmaceutical Industries Inc. | 10 | $559 |
| Regeneron Healthcare Solutions, Inc. | 32 | $496 |
| Dermavant Sciences, Inc. | 9 | $461 |
| Galderma Laboratories, L.p. | 3 | $455 |
| Amgen | 19 | $415 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $368 |
| E.r. Squibb & Sons, L.L.C. | 9 | $325 |
| UCB, Inc. | 4 | $319 |
| Mayne Pharma Commercial LLC | 16 | $269 |
| Merz North America, Inc. | 3 | $211 |
| Boehringer Ingelheim | 3 | $188 |
| VYNE Pharmaceuticals Inc. | 10 | $169 |
| Lilly USA, LLC | 3 | $159 |
| Arcutis Biotherapeutics, Inc. | 1 | $147 |
| Urgo Medical North America, LLC | 1 | $125 |
| Johnson & Johnson | 1 | $125 |
| Boston Scientific | 1 | $109 |
| Almirall LLC | 5 | $90 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $89 |
| EPI Health, LLC | 3 | $75 |
| Incyte Corporation | 3 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Organon | 2 | $43 |
| Mission Pharmacal Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$5,895
- DUPIXENT$4,466
- SILIQ$279
- ARAZLO$279
- VTAMA$262
- XEOMIN$192
- EPIDUO FORTE$189
- Cabtreo$143
- DUOBRII$143
- Winlevi$139
- TARGRETIN$135
- JUBLIA$135
- VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP$125
- DRAWTEX HYDROCONDUCTIVE WOUND DRESSING WITH LEVAFIBER 4X4$125
- UrgoK2$125
- ILUMYA$125
- Tremfya$125
- SPEVIGO$124
- EUCRISA$118
- Sotyktu$112
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.